408 related articles for article (PubMed ID: 23919111)
21. Cholangiocarcinoma: a site-specific update on the current state of surgical management and multi-modality therapy.
Turgeon MK; Maithel SK
Chin Clin Oncol; 2020 Feb; 9(1):4. PubMed ID: 31500433
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis.
Eckmann KR; Patel DK; Landgraf A; Slade JH; Lin E; Kaur H; Loyer E; Weatherly JM; Javle M
Gastrointest Cancer Res; 2011 Sep; 4(5-6):155-60. PubMed ID: 22295126
[TBL] [Abstract][Full Text] [Related]
23. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
24. Systemic treatment of advanced or recurrent biliary tract cancer.
Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
[TBL] [Abstract][Full Text] [Related]
25. Hilar cholangiocarcinoma: expert consensus statement.
Mansour JC; Aloia TA; Crane CH; Heimbach JK; Nagino M; Vauthey JN
HPB (Oxford); 2015 Aug; 17(8):691-9. PubMed ID: 26172136
[TBL] [Abstract][Full Text] [Related]
26. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians.
Moris D; Palta M; Kim C; Allen PJ; Morse MA; Lidsky ME
CA Cancer J Clin; 2023 Mar; 73(2):198-222. PubMed ID: 36260350
[TBL] [Abstract][Full Text] [Related]
27. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach.
Merath K; Tiwari A; Parikh AA; Pawlik TM
Future Oncol; 2023 Dec; 19(39):2607-2621. PubMed ID: 38108100
[TBL] [Abstract][Full Text] [Related]
28. Intrahepatic cholangiocarcinoma: expert consensus statement.
Weber SM; Ribero D; O'Reilly EM; Kokudo N; Miyazaki M; Pawlik TM
HPB (Oxford); 2015 Aug; 17(8):669-80. PubMed ID: 26172134
[TBL] [Abstract][Full Text] [Related]
29. Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer.
Jonker D; Rumble RB; Maroun J;
Curr Oncol; 2006 Oct; 13(5):173-84. PubMed ID: 22792014
[TBL] [Abstract][Full Text] [Related]
30. Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?
Fenocchio E; Filippi R; Lombardi P; Quarà V; Milanesio M; Aimar G; Leone F; Aglietta M
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31614884
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of neoadjuvant chemotherapy based on our resectability criteria for locally advanced perihilar cholangiocarcinoma.
Gyoten K; Kuriyama N; Maeda K; Ito T; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Murata Y; Kishiwada M; Mizuno S
Langenbecks Arch Surg; 2023 Jul; 408(1):261. PubMed ID: 37392289
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100334. PubMed ID: 33592563
[TBL] [Abstract][Full Text] [Related]
33. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP
Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
[TBL] [Abstract][Full Text] [Related]
35. A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada.
Ramjeesingh R; Chaudhury P; Tam VC; Roberge D; Lim HJ; Knox JJ; Asselah J; Doucette S; Chhiber N; Goodwin R
Curr Oncol; 2023 Jul; 30(8):7132-7150. PubMed ID: 37622998
[TBL] [Abstract][Full Text] [Related]
36. Medical treatment for cholangiocarcinoma.
Adeva J; Sangro B; Salati M; Edeline J; La Casta A; Bittoni A; Berardi R; Bruix J; Valle JW
Liver Int; 2019 May; 39 Suppl 1():123-142. PubMed ID: 30892822
[TBL] [Abstract][Full Text] [Related]
37. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
38. Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma.
Nakeeb A; Pitt HA
HPB (Oxford); 2005; 7(4):278-82. PubMed ID: 18333207
[TBL] [Abstract][Full Text] [Related]
39. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
40. [Medical management of cholangiocarcinomas in 2015].
Marret G; Neuzillet C; Rousseau B; Tournigand C
Bull Cancer; 2016 Apr; 103(4):389-99. PubMed ID: 26922666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
